Markus A. Weigand

Heidelberg University

Papers

2

Total Citations

110

H-Index

2

About

Dr. Markus A. Weigand is a leading clinician-scientist whose work bridges critical care medicine and advanced surgical oncology. His primary research focuses on the rapid diagnosis and management of life-threatening infections, particularly sepsis and bloodstream infections in intensive care unit patients. Dr. Weigand’s landmark 2020 study on next-generation sequencing for bacteremia diagnostics (94 citations) demonstrated a paradigm shift away from slow, culture-based methods, offering a pathway to faster, more precise pathogen identification and targeted antibiotic therapy—a critical advance in combating sepsis mortality. In parallel, he is a key figure in esophageal cancer surgery, serving as a principal investigator for the landmark MIVATE trial (16 citations), which rigorously compares minimally invasive versus open abdomino-thoracic esophagectomy. This work aims to define the optimal surgical approach to reduce postoperative complications while maintaining oncologic outcomes. With a career dedicated to translating cutting-edge molecular diagnostics and refining high-risk surgical techniques, Dr. Weigand’s research directly impacts patient survival and recovery in two of the most challenging fields in modern medicine.

Research Focus

Key Achievements

2
H-Index
2
Papers
110
Total Citations
55
Avg Citations/Paper
🏆 Most Cited Paper
Rapid Next-Generation Sequencing–Based Diagnostics of Bacteremia in Septic Patients
94 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 22
🏛 Institutions: Heidelberg University

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago